These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1518 related articles for article (PubMed ID: 28404761)

  • 41. [Prevention, diagnosis, therapy, and follow-up of lung cancer].
    Goeckenjan G; Sitter H; Thomas M; Branscheid D; Flentje M; Griesinger F; Niederle N; Stuschke M; Blum T; Deppermann KM; Ficker JH; Freitag L; Lübbe AS; Reinhold T; Späth-Schwalbe E; Ukena D; Wickert M; Wolf M; Andreas S; Auberger T; Baum RP; Baysal B; Beuth J; Bickeböller H; Böcking A; Bohle RM; Brüske I; Burghuber O; Dickgreber N; Diederich S; Dienemann H; Eberhardt W; Eggeling S; Fink T; Fischer B; Franke M; Friedel G; Gauler T; Gütz S; Hautmann H; Hellmann A; Hellwig D; Herth F; Heussel CP; Hilbe W; Hoffmeyer F; Horneber M; Huber RM; Hübner J; Kauczor HU; Kirchbacher K; Kirsten D; Kraus T; Lang SM; Martens U; Mohn-Staudner A; Müller KM; Müller-Nordhorn J; Nowak D; Ochmann U; Passlick B; Petersen I; Pirker R; Pokrajac B; Reck M; Riha S; Rübe C; Schmittel A; Schönfeld N; Schütte W; Serke M; Stamatis G; Steingräber M; Steins M; Stoelben E; Swoboda L; Teschler H; Tessen HW; Weber M; Werner A; Wichmann HE; Irlinger Wimmer E; Witt C; Worth H;
    Pneumologie; 2010 Mar; 64 Suppl 2():e1-164. PubMed ID: 20217630
    [No Abstract]   [Full Text] [Related]  

  • 42. Molecular markers related to immunosurveillance as predictive and monitoring tools in non-small cell lung cancer: recent accomplishments and future promises.
    Michaelidou K; Agelaki S; Mavridis K
    Expert Rev Mol Diagn; 2020 Mar; 20(3):335-344. PubMed ID: 32000550
    [No Abstract]   [Full Text] [Related]  

  • 43. Toxicity with small molecule and immunotherapy combinations in non-small cell lung cancer.
    Adderley H; Blackhall FH; Lindsay CR
    Cancer Immunol Immunother; 2021 Mar; 70(3):589-595. PubMed ID: 32915318
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Immunotherapy and lung cancer: current developments and novel targeted therapies.
    Domingues D; Turner A; Silva MD; Marques DS; Mellidez JC; Wannesson L; Mountzios G; de Mello RA
    Immunotherapy; 2014; 6(11):1221-35. PubMed ID: 25496336
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Non-small-cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up.
    D'Addario G; Felip E;
    Ann Oncol; 2009 May; 20 Suppl 4():68-70. PubMed ID: 19454467
    [No Abstract]   [Full Text] [Related]  

  • 46. Review of treatment options for oligometastatic non-small cell lung cancer.
    Folkert MR; Timmerman R
    Clin Adv Hematol Oncol; 2015 Mar; 13(3):186-93. PubMed ID: 26352427
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Management of non-small-cell lung carcinoma (NSCLC) of stage III B].
    Koukourakis M
    Rev Pneumol Clin; 2001 Nov; 57(5 Pt 2):S33-6. PubMed ID: 11924241
    [No Abstract]   [Full Text] [Related]  

  • 48. [National consensus of diagnosis and treatment of non-small cell lung cancer].
    Arrieta O; Guzmán-de Alba E; Alba-López LF; Acosta-Espinoza A; Alatorre-Alexander J; Alexander-Meza JF; Allende-Pérez SR; Alvarado-Aguilar S; Araujo-Navarrete ME; Argote-Greene LM; Aquino-Mendoza CA; Astorga-Ramos AM; Austudillo-de la Vega H; Avilés-Salas A; Barajas-Figueroa LJ; Barroso-Quiroga N; Blake-Cerda M; Cabrera-Galeana PA; Calderillo-Ruíz G; Campos-Parra AD; Cano-Valdez AM; Capdeville-García D; Castillo-Ortega G; Casillas-Suárez C; Castillo-González P; Corona-Cruz JF; Correa-Acevedo ME; Cortez-Ramírez SS; de la Cruz-Vargas JA; de la Garza-Salazar JG; de la Mata-Moya MD; Domínguez-Flores ME; Domínguez-Malagón HR; Domínguez-Parra LM; Domínguez-Peregrina A; Durán-Alcocer J; Enríquez-Aceves MI; Elizondo-Ríos A; Escobedo-Sánchez MD; de Villafranca PE; Flores-Cantisani A; Flores-Gutiérrez JP; Franco-Marina F; Franco-González EE; Franco-Topete RA; Fuentes-de la Peña H; Galicia-Amor S; Gallardo-Rincón D; Gamboa-Domínguez A; García-Andreu J; García-Cuéllar CM; García-Sancho-Figueroa MC; García-Torrentera R; Gerson-Cwilich R; Gómez-González A; Green-Schneeweiss L; Guillén-Núñez Mdel R; Gutiérrez-Velázquez H; Ibarra-Pérez C; Jiménez-Fuentes E; Juárez-Sánchez P; Juárez-Ramiro A; Kelly-García J; Kuri-Exsome R; Lázaro-León JM; León-Rodríguez E; Llanos-Osuna S; Llanos-Osuna S; Loyola-García U; López-González JS; López y de Antuñano FJ; Loustaunau-Andrade MA; Macedo-Pérez EO; Machado-Villarroel L; Magallanes-Maciel M; Martínez-Barrera L; Martínez-Cedillo J; Martínez-Martínez G; Medina-Esparza A; Meneses-García A; Mohar-Betancourt A; Morales Blanhir J; Morales-Gómez J; Motola-Kuba D; Nájera-Cruz MP; Núñez-Valencia Cdel C; Ocampo-Ocampo MA; Ochoa-Vázquez MD; Olivares-Torres CA; Palomar-Lever A; Patiño-Zarco M; Pérez-Padilla R; Peña-Alonso YR; Pérez-Romo AR; Aquilino Pérez M; Pinaya-Ruíz PM; Pointevin-Chacón MA; Poot-Braga JJ; Posadas-Valay R; Ramirez-Márquez M; Reyes-Martínez I; Robledo-Pascual J; Rodríguez-Cid J; Rojas-Marín CE; Romero-Bielma E; Rubio-Gutiérrez JE; Sáenz-Frías JA; Salazar-Lezama MA; Sánchez-Lara K; Sansores Martínez R; Santillán-Doherty P; Alejandro-Silva J; Téllez-Becerra JL; Toledo-Buenrostro V; Torre-Bouscoulet L; Torecillas-Torres L; Torres M; Tovar-Guzmán V; Turcott-Chaparro JG; Vázquez-Cortés JJ; Vázquez-Manríquez ME; Vilches-Cisneros N; Villegas-Elizondo JF; Zamboni MM; Zamora-Moreno J; Zinser-Sierra JW
    Rev Invest Clin; 2013 Mar; 65 Suppl 1():S5-84. PubMed ID: 24459776
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Perceptions of prognosis, treatment, and treatment impact on prognosis in non-small cell lung cancer.
    Perez EA
    Chest; 1998 Aug; 114(2):593-604. PubMed ID: 9726750
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Low level evidence supporting the choice of optimal multimodality treatment approach in patients with stage IIIA NSCLC- Ain't no mountain high enough…. to keep me getting to you.
    Jeremic B; Gomez-Caamano A; Dubinsky P; Cihoric N; Igrutinovic I; Videtic G
    Lung Cancer; 2018 Sep; 123():172-173. PubMed ID: 29921448
    [No Abstract]   [Full Text] [Related]  

  • 51. Long term disease-free survival resulting from combined modality management of patients presenting with oligometastatic, non-small cell lung carcinoma (NSCLC).
    Khan AJ; Mehta PS; Zusag TW; Bonomi PD; Penfield Faber L; Shott S; Abrams RA
    Radiother Oncol; 2006 Nov; 81(2):163-7. PubMed ID: 17050016
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Review of economic analyses of treatment for non-small-cell lung cancer (NSCLC).
    Vergnenègre A; Chouaïd C
    Expert Rev Pharmacoecon Outcomes Res; 2018 Oct; 18(5):519-528. PubMed ID: 29869900
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Advances in the treatment of non-small cell lung cancer.
    Horn L
    J Natl Compr Canc Netw; 2014 May; 12(5 Suppl):764-7. PubMed ID: 24853212
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinical trials referral resource. Clinical trials in lung cancer.
    Feigal EG; Cheson BD; Nelson AP
    Oncology (Williston Park); 1997 Nov; 11(11):1686, 1688, 1691, 1694. PubMed ID: 9394366
    [No Abstract]   [Full Text] [Related]  

  • 55. Leptomeningeal Metastases in Non-small Cell Lung Cancer: Optimal Systemic Management in NSCLC With and Without Driver Mutations.
    Alexander M; Lin E; Cheng H
    Curr Treat Options Oncol; 2020 Jul; 21(9):72. PubMed ID: 32725549
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Lung cancer: current therapies and new targeted treatments.
    Hirsch FR; Scagliotti GV; Mulshine JL; Kwon R; Curran WJ; Wu YL; Paz-Ares L
    Lancet; 2017 Jan; 389(10066):299-311. PubMed ID: 27574741
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Update 2020: Management of Non-Small Cell Lung Cancer.
    Alexander M; Kim SY; Cheng H
    Lung; 2020 Dec; 198(6):897-907. PubMed ID: 33175991
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Practice guidelines for non-small cell lung cancer.
    Cameron R; Fringer J; Taylor C; Gilden CR; Figlin RA
    Cancer J Sci Am; 1996; 2(3A Suppl):S61-8. PubMed ID: 9166525
    [No Abstract]   [Full Text] [Related]  

  • 59. Response to: Low level evidence supporting the choice of optimal multimodality treatment approach in patients with stage IIIA NSCLC- ain't no mountain high enough…. to keep me getting to you by Jeremic Branislav.
    Couñago F; de Dios NR; Montemuiño S; Jové-Teixidó J; Martin M; Calvo-Crespo P; López-Mata M; Samper-Ots MP; López-Guerra JL; García-Cañibano T; Díaz-Díaz V; de Ingunza-Barón L; Murcia-Mejía M; Alcántara P; Corona J; Puertas MM; Chust M; Couselo ML; Del Cerro E; Moradiellos J; Amor S; Varela A; Thuissard IJ; Sanz-Rosa D; Taboada B
    Lung Cancer; 2018 Sep; 123():174-175. PubMed ID: 30017426
    [No Abstract]   [Full Text] [Related]  

  • 60. Predictive impact for postoperative recurrence using the preoperative prognostic nutritional index in pathological stage I non-small cell lung cancer.
    Shoji F; Morodomi Y; Akamine T; Takamori S; Katsura M; Takada K; Suzuki Y; Fujishita T; Okamoto T; Maehara Y
    Lung Cancer; 2016 Aug; 98():15-21. PubMed ID: 27393501
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 76.